FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3007238468> ?p ?o ?g. }

• W3007238468 endingPage "541" @default.
• W3007238468 startingPage "533" @default.
• W3007238468 abstract "Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept - A Retrospective Cohort Study Christoph Kern,1,2 Johannes Schiefelbein,1 Dun Jack Fu,2 Benedikt Schworm,1 Dawn Sim,2 Tina Herold,1 Siegfried Priglinger,1 Karsten Kortuem1,2 1Department of Ophthalmology, University Hospital LMU, Munich, Germany; 2Moorfields Eye Hospital, London, UKCorrespondence: Christoph KernDepartment of Ophthalmology, University Hospital, LMU Munich, Mathildenstraße 8, Munich 80336, GermanyTel +49 89 4400 53812Email Christoph.kern@med.uni-muenchen.dePurpose: To assess visual and anatomical outcomes of intravitreal aflibercept for clinically significant diabetic macular oedema (DME).Methods: For this retrospective single-center cohort study at a tertiary referral center, we performed a data warehouse query to identify 117 treatment-naive patients (139 eyes) undergoing intravitreal treatment with aflibercept for DME between January 2014 and May 2018. Changes in best-corrected visual acuity (BCVA) values (as measured with ETDRS letters), central retinal thickness (CRT) and total macular volume (TVOL) are reported over a two-year period at various time-points.Results: The total number of injections per study eye was 5.5 ± 1.4 after one and 8.7 ± 2.2 injections after two years. Baseline visual acuity (VA) was 60.1 ± 14.5 letters. A gain of 4.8 and 9.2 letters from baseline was observed after one and two years, respectively (both p ≤ 0.01). In comparison to the mean CRT at baseline (419 ± 174 μm), a CRT decrease was observed after one and two years of treatment (298 ± 115 μm and 319 ± 119 μm, respectively; both p ≤ 0.01). Similarly, TVOL decreased from 10.12 ± 2.05 mm3 to 8.96 ± 0.96 mm3 and 9.01 ± 1.29 mm3 (both p ≤ 0.01).Conclusion: This study demonstrates that treating DME with intravitreal aflibercept yields positive functional and structural outcomes over a two-year period. However, we observed fewer injection numbers, along with inferior VA and structural outcomes than has been reported in randomized clinical trials. Our results show similar results as in patients treated with ranibizumab due to DME in real-life settings.Keywords: aflibercept, diabetic macular oedema, visual acuity, central retinal thickness" @default.
• W3007238468 created "2020-03-06" @default.
• W3007238468 creator A5029287441 @default.
• W3007238468 creator A5037304973 @default.
• W3007238468 creator A5049721803 @default.
• W3007238468 creator A5066229916 @default.
• W3007238468 creator A5075539836 @default.
• W3007238468 creator A5083191480 @default.
• W3007238468 creator A5088003995 @default.
• W3007238468 creator A5090058552 @default.
• W3007238468 date "2020-02-01" @default.
• W3007238468 modified "2023-09-25" @default.
• W3007238468 title "<p>Two Year Visual Acuity and Structural Outcomes in Patients with Diabetic Macular Oedema Treated with Intravitreal Aflibercept – A Retrospective Cohort Study</p>" @default.
• W3007238468 cites W1984158303 @default.
• W3007238468 cites W2013188809 @default.
• W3007238468 cites W2036712095 @default.
• W3007238468 cites W2052023322 @default.
• W3007238468 cites W2094007374 @default.
• W3007238468 cites W2102463203 @default.
• W3007238468 cites W2104740524 @default.
• W3007238468 cites W2161279821 @default.
• W3007238468 cites W2161588304 @default.
• W3007238468 cites W2168261002 @default.
• W3007238468 cites W2173144648 @default.
• W3007238468 cites W2289200040 @default.
• W3007238468 cites W2305024821 @default.
• W3007238468 cites W2400484325 @default.
• W3007238468 cites W2500843454 @default.
• W3007238468 cites W2518713733 @default.
• W3007238468 cites W2521813548 @default.
• W3007238468 cites W2558041207 @default.
• W3007238468 cites W2602302047 @default.
• W3007238468 cites W2616361514 @default.
• W3007238468 cites W2669540614 @default.
• W3007238468 cites W2745245276 @default.
• W3007238468 cites W2748811507 @default.
• W3007238468 cites W2766315223 @default.
• W3007238468 cites W2799551240 @default.
• W3007238468 cites W2800700913 @default.
• W3007238468 cites W2887101278 @default.
• W3007238468 cites W2894823502 @default.
• W3007238468 cites W2894838826 @default.
• W3007238468 cites W2916293705 @default.
• W3007238468 cites W2963068069 @default.
• W3007238468 cites W3118188575 @default.
• W3007238468 cites W4210243734 @default.
• W3007238468 cites W4211205882 @default.
• W3007238468 cites W4285698150 @default.
• W3007238468 doi "https://doi.org/10.2147/opth.s237586" @default.
• W3007238468 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7049742" @default.
• W3007238468 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32161438" @default.
• W3007238468 hasPublicationYear "2020" @default.
• W3007238468 type Work @default.
• W3007238468 sameAs 3007238468 @default.
• W3007238468 citedByCount "8" @default.
• W3007238468 countsByYear W30072384682021 @default.
• W3007238468 countsByYear W30072384682022 @default.
• W3007238468 countsByYear W30072384682023 @default.
• W3007238468 crossrefType "journal-article" @default.
• W3007238468 hasAuthorship W3007238468A5029287441 @default.
• W3007238468 hasAuthorship W3007238468A5037304973 @default.
• W3007238468 hasAuthorship W3007238468A5049721803 @default.
• W3007238468 hasAuthorship W3007238468A5066229916 @default.
• W3007238468 hasAuthorship W3007238468A5075539836 @default.
• W3007238468 hasAuthorship W3007238468A5083191480 @default.
• W3007238468 hasAuthorship W3007238468A5088003995 @default.
• W3007238468 hasAuthorship W3007238468A5090058552 @default.
• W3007238468 hasBestOaLocation W30072384681 @default.
• W3007238468 hasConcept C118487528 @default.
• W3007238468 hasConcept C119767625 @default.
• W3007238468 hasConcept C126322002 @default.
• W3007238468 hasConcept C134018914 @default.
• W3007238468 hasConcept C141071460 @default.
• W3007238468 hasConcept C167135981 @default.
• W3007238468 hasConcept C2776694085 @default.
• W3007238468 hasConcept C2777802072 @default.
• W3007238468 hasConcept C2778257484 @default.
• W3007238468 hasConcept C2778749236 @default.
• W3007238468 hasConcept C2779829184 @default.
• W3007238468 hasConcept C555293320 @default.
• W3007238468 hasConcept C71924100 @default.
• W3007238468 hasConcept C72563966 @default.
• W3007238468 hasConceptScore W3007238468C118487528 @default.
• W3007238468 hasConceptScore W3007238468C119767625 @default.
• W3007238468 hasConceptScore W3007238468C126322002 @default.
• W3007238468 hasConceptScore W3007238468C134018914 @default.
• W3007238468 hasConceptScore W3007238468C141071460 @default.
• W3007238468 hasConceptScore W3007238468C167135981 @default.
• W3007238468 hasConceptScore W3007238468C2776694085 @default.
• W3007238468 hasConceptScore W3007238468C2777802072 @default.
• W3007238468 hasConceptScore W3007238468C2778257484 @default.
• W3007238468 hasConceptScore W3007238468C2778749236 @default.
• W3007238468 hasConceptScore W3007238468C2779829184 @default.
• W3007238468 hasConceptScore W3007238468C555293320 @default.
• W3007238468 hasConceptScore W3007238468C71924100 @default.
• W3007238468 hasConceptScore W3007238468C72563966 @default.
• W3007238468 hasLocation W30072384681 @default.
• W3007238468 hasLocation W30072384682 @default.

• next